Private Equity Buys Another Piece of Baxter as Carlyle Scoops Up Kidney Care Biz for $3.8B
Baxter International is selling its kidney care business for less than it was able to fetch for its much smaller biopharma solutions segment last year. A unit within kidney care took a goodwill impairment charge, Baxter’s financial reports show.
